News Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:29:04 05/08/26 am AEST			5-day change	1st Jan Change
16.19 ^USD	+5.27%		-26.23%	+3.70%

01/08	Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial	MT
01/08	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT

All News

Mentions Relevance

01/08	Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating	MT
03/07	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark	CI
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index	CI
30/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000 Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000 Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Small Cap Comp Value Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark	CI
29/06	Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2500 Value Benchmark	CI
03/06	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	AQ
08/05	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Monte Rosa Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M	MT
07/05	Monte Rosa Therapeutics : Corporate Presentation – May 2026	PU
07/05	Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates	AQ
06/05	Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
22/04	Monte Rosa Therapeutics : AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	PU
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	GL
20/04	Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors	CI